CMPS | Jotup

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

Retrieved on:

onsdag, maj 8, 2024

“These results, with early and lasting improvement in symptoms following a single administration of COMP360, are highly encouraging,” said Dr.

Key Points:

“These results, with early and lasting improvement in symptoms following a single administration of COMP360, are highly encouraging,” said Dr.
“These observations, even with a small, open-label study, suggest that COMP360 could provide a clinically meaningful benefit and substantially improve patient daily function and quality of life.
The well tolerated safety profile for COMP360 in patients with PTSD, with no serious adverse events observed, advance our understanding of potential applications of COMP360.
Compass previously announced 24-hour safety data from the study, which indicated that COMP360 was well-tolerated, with no treatment emergent serious adverse events.

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights

Retrieved on:

onsdag, maj 8, 2024

FDA, Research, PTSD, MD, Depression, Webcast, TRD, Mental health, Patient, Pivotal, DSM-IV codes, Gold, Anorexia nervosa, Drug development, Therapy, CMPS, Pharmaceutical industry

Second quarter 2024 net cash used in operating activities is expected to be in the range of $32 million to $38 million.

Key Points:

Second quarter 2024 net cash used in operating activities is expected to be in the range of $32 million to $38 million.
The Compass Pathways management team will host a conference call at 8:00am ET (1:00pm UK) on May 8, 2024.
A live webcast of the call will be available on Compass Pathway’s website at: First Quarter 2024 Financial Results .
The call will also be webcast on the Compass Pathways website and archived for 30 days.

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors

Retrieved on:

torsdag, mars 28, 2024

Patient, Chairperson, CNS, Mental health, Innovation, CMPS, Psilocybin, TRD, Johnson & Johnson, Operation, Pain, KCL, Frustration, J&J, Food, Nursing

David Norton, lead independent director on the Compass board of directors, will become interim chair.

Key Points:

David Norton, lead independent director on the Compass board of directors, will become interim chair.
Compass is running a global search for a permanent board chair, focused on recruiting a leader with a strong background in the biotechnology sector and broad strategic experience across the product lifecycle.
“When we started Compass eight years ago, we could not have imagined how the company would grow and mature,” said George Goldsmith, outgoing board chair of Compass Pathways.
He has been a member of the Compass board of directors since 2018, serving as lead independent director.

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights

Retrieved on:

torsdag, februari 29, 2024

Mental health, Research, HMRC, FDA, Compass, COMP, Safety, Post-traumatic stress disorder, Webcast, Health, Patient, PTSD, G&A, Pivotal, CMPS, Depression

Research and development (R&D) expenses were $87.5 million for the year ended December 31, 2023, compared with $65.1 million during the same period in 2022.

Key Points:

Research and development (R&D) expenses were $87.5 million for the year ended December 31, 2023, compared with $65.1 million during the same period in 2022.
The Compass Pathways management team will host a conference call at 8.00am ET (1:00pm UK) on February 29, 2024.
A live webcast of the call will be available on Compass Pathway’s website at: Fourth Quarter 2023 Financial Results .
The call will also be webcast on the Compass Pathways website and archived for 30 days.

How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

Retrieved on:

onsdag, januari 24, 2024

PALM BEACH, Fla., Jan. 24, 2024 /PRNewswire/ -- The coming years could see a massive shift in the U.S. government's approach to regulating hallucinogenic drugs. Several biopharma companies are developing psychedelics-based treatments for various mental health conditions like Generalized Anxiety Disorder (GAD). GAD is a prevalent mental health condition characterized by excessive and persistent worry, often extending beyond specific triggers. Individuals with GAD experience heightened levels of anxiety, anticipating future events and exhibiting physical symptoms such as muscle tension and restlessness. The disorder significantly impairs daily functioning and quality of life. A report from Delveinsight said that the total market size of the Generalized Anxiety Disorder (GAD) treatment market is anticipated to experience growth during the forecast period (2032) due to the emergence of new and effective treatments, especially numerous trials developing new and innovative next-generation psychedelic treatment options. The report added: "The diagnosis of Generalized Anxiety Disorder (GAD) involves a comprehensive assessment of an individual's mental health, considering the presence of excessive and uncontrollable worry across various aspects of life for a minimum of six months. Clinicians utilize standardized psychiatric interviews and validated screening tools to evaluate the severity of anxiety symptoms, along with a thorough exploration of associated physical and psychological manifestations. Differential diagnosis is crucial to rule out other psychiatric conditions, medical disorders, or substance-related issues that may mimic GAD symptoms. The diagnostic process also entails considering the impact of anxiety on daily functioning and its persistence in the absence of identifiable stressors. A multidimensional approach aids in ensuring an accurate diagnosis and facilitates the development of an effective treatment plan tailored to the individual's needs." Active Companies active today in markets include: Cybin Inc. (NYSE: CYBN) (NEO: CYBN), COMPASS Pathways plc (NASDAQ: CMPS), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), Seelos Therapeutics, Inc. (NASDAQ: SEEL), atai Life Sciences (NASDAQ: ATAI).

Key Points:

Several biopharma companies are developing psychedelics-based treatments for various mental health conditions like Generalized Anxiety Disorder (GAD).
It continued: "DelveInsight's analyst projects that among the total diagnosed prevalent cases of Generalized Anxiety Disorder (GAD) in 7MM approximately 53% of cases were from the US.
The Generalized Anxiety Disorder (GAD) market is projected to witness consistent growth throughout the forecast period (2023–2032).
The market size of Generalized Anxiety Disorder (GAD) in the 7MM is expected to increase, driven by better diagnosis and the launch of emerging therapies."

How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

Retrieved on:

onsdag, januari 24, 2024

PALM BEACH, Fla., Jan. 24, 2024 /PRNewswire/ -- The coming years could see a massive shift in the U.S. government's approach to regulating hallucinogenic drugs. Several biopharma companies are developing psychedelics-based treatments for various mental health conditions like Generalized Anxiety Disorder (GAD). GAD is a prevalent mental health condition characterized by excessive and persistent worry, often extending beyond specific triggers. Individuals with GAD experience heightened levels of anxiety, anticipating future events and exhibiting physical symptoms such as muscle tension and restlessness. The disorder significantly impairs daily functioning and quality of life. A report from Delveinsight said that the total market size of the Generalized Anxiety Disorder (GAD) treatment market is anticipated to experience growth during the forecast period (2032) due to the emergence of new and effective treatments, especially numerous trials developing new and innovative next-generation psychedelic treatment options. The report added: "The diagnosis of Generalized Anxiety Disorder (GAD) involves a comprehensive assessment of an individual's mental health, considering the presence of excessive and uncontrollable worry across various aspects of life for a minimum of six months. Clinicians utilize standardized psychiatric interviews and validated screening tools to evaluate the severity of anxiety symptoms, along with a thorough exploration of associated physical and psychological manifestations. Differential diagnosis is crucial to rule out other psychiatric conditions, medical disorders, or substance-related issues that may mimic GAD symptoms. The diagnostic process also entails considering the impact of anxiety on daily functioning and its persistence in the absence of identifiable stressors. A multidimensional approach aids in ensuring an accurate diagnosis and facilitates the development of an effective treatment plan tailored to the individual's needs." Active Companies active today in markets include: Cybin Inc. (NYSE: CYBN) (NEO: CYBN), COMPASS Pathways plc (NASDAQ: CMPS), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), Seelos Therapeutics, Inc. (NASDAQ: SEEL), atai Life Sciences (NASDAQ: ATAI).

Key Points:

Several biopharma companies are developing psychedelics-based treatments for various mental health conditions like Generalized Anxiety Disorder (GAD).
It continued: "DelveInsight's analyst projects that among the total diagnosed prevalent cases of Generalized Anxiety Disorder (GAD) in 7MM approximately 53% of cases were from the US.
The Generalized Anxiety Disorder (GAD) market is projected to witness consistent growth throughout the forecast period (2023–2032).
The market size of Generalized Anxiety Disorder (GAD) in the 7MM is expected to increase, driven by better diagnosis and the launch of emerging therapies."

Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved

Retrieved on:

tisdag, januari 16, 2024

Patient, Depression, Hospital, Health, Hackensack University Medical Center, Mental health, Hackensack Meridian Health, News, HMH, FDA, Compass, CMPS, Nursing

The collaboration between Compass and HMH aims to improve health outcomes and improve patient and provider experiences for mental health conditions such as treatment-resistant depression.

Key Points:

The collaboration between Compass and HMH aims to improve health outcomes and improve patient and provider experiences for mental health conditions such as treatment-resistant depression.
COMP360 is Compass’s investigational proprietary formulation of synthetic psilocybin, administered in conjunction with psychological support.
Hackensack Meridian Health offers a complete range of medical services, innovative research and life-enhancing care.
“We’re proud to collaborate with Compass Pathways, a leading biotechnology company aiming to create real change for people suffering with some of the most difficult-to-treat mental health conditions,” said Robert C. Garrett, FACHE, CEO of Hackensack Meridian Health.

Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement

Retrieved on:

fredag, januari 5, 2024

Food, Research, FDA, DSM-IV codes, Health, United, Mental health, Transcranial magnetic stimulation, Patient, TRD, CMPS

The collaboration will research and investigate models for the delivery of scalable, commercial COMP360 within healthcare systems, assuming FDA approval.

Key Points:

The collaboration will research and investigate models for the delivery of scalable, commercial COMP360 within healthcare systems, assuming FDA approval.
In-depth research will include exploring how to improve the patient care experience and gaining a better understanding of therapist needs and investigating the potential use and integration of digital tools within Greenbrook TMS’s existing care pathways.
Compass has commenced a phase 3 clinical program of COMP360 in TRD and intends to apply for FDA approval upon completion of clinical trials.
“We’re pleased to enter into this research collaboration with Greenbrook TMS to learn how this can be optimized at scale and in the most cost-effective way for our healthcare systems if COMP360 receives regulatory approval.”
“We are proud to collaborate with Compass to explore how we can bring innovative treatments to patients safely and conveniently,” said Bill Leonard, President and Chief Executive Officer of Greenbrook TMS.

Investor Ideas Potcasts: Interview with Kaya Holdings on the Sacred Mushroom Center - Pioneers with Psilocybin and Advocates for Mental Health

Retrieved on:

tisdag, november 28, 2023

Psilocybin, Sound, Interview, Disorder, System, FDA, Research, Heart, Mental health, Love, Mental disorder, Food, CMPS, Child, Tourism

Kaya Holdings, Inc. is a mind care company focusing on wellness and mental health through their operations in medical and recreational cannabis, CBD products and psychedelic treatment clinics.

Key Points:

Kaya Holdings, Inc. is a mind care company focusing on wellness and mental health through their operations in medical and recreational cannabis, CBD products and psychedelic treatment clinics.
In today's podcast, management discusses the new opportunities in the medical psychedelic market and how Kaya Holdings is leading the way as an innovator and pioneer in the sector.
They also talk about their recent milestone of opening one of the first state licensed Psilocybin Treatment Centers in the United States, in Portland, Oregon.
We discuss mental health and how it personally affects us all.

Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder

Retrieved on:

tisdag, december 19, 2023

Trauma, The Institute, Psilocybin, Lead, Psychiatrist, Mental health, PTSD, Sunstone, Post-traumatic stress disorder, Psychology, Safety, Patient, CMPS, Pharmaceutical industry

This is believed to be the first study reporting on the feasibility of psilocybin as a potential treatment for PTSD.

Key Points:

This is believed to be the first study reporting on the feasibility of psilocybin as a potential treatment for PTSD.
The open-label study evaluated the safety and tolerability of COMP360 psilocybin treatment in patients with PTSD as a result of trauma experienced as adults.
22 participants received a single 25mg dose of investigational COMP360 psilocybin treatment.
It’s encouraging to see these initial safety results for COMP360 psilocybin treatment in this patient population and we look forward to a more detailed analysis of the study next year.”